SCHEMBL20436304

SCHEMBL20436304

Cc1cccc(NC(=O)N2CCCC2C(=O)O)c1-c1c(C)cccc1N(C)C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 2/20 0.68
▸ ITGB1 P05556 2/20 0.68
▸ ITGAV P06756 2/20 0.68
▸ ITGA5 P08648 2/20 0.68
▸ ITGA4 P13612 2/20 0.68
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ TSHR P16473 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20436308 0.89 ITGB3 (0.64) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL24200375 0.87 ITGB3 (0.74) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL20436306 0.78 ITGB3 (0.55) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL5763695 0.73 ITGB1 (0.79) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL20421627 0.72 ALDH1A1 (0.54) KMT2AALDH1A1MEN1TDP1TSHR
SCHEMBL5105015 0.72 ITGB3 (0.72) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL16105033 0.71 ITGB3 (0.70) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL16105032 0.71 ITGB3 (0.70) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL4186674 0.70 KMT2A (0.76) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL16098444 0.69 ITGB3 (0.67) ITGB3ITGB1ITGAVITGA5ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11327060-B2 Method for analyzing enantiomer AJINOMOTO CO., INC. (JP) 2022-05-10 — — US disclosed
EP-3358346-A1 ENANTIOMER ANALYSIS METHOD Ajinomoto Co., Inc. (JP) 2018-08-08 — — EP disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11327060-B2 Method for analyzing enantiomer DCX, INF2, SRD5A2 ITGB3 4498/4885ITGB1 4615/4885ITGAV 4755/4885
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER DCX, INF2, SRD5A2 ITGB3 4498/4885ITGB1 4615/4885ITGAV 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback